Compare CNXN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | NRIX |
|---|---|---|
| Founded | 1982 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1997 | 2020 |
| Metric | CNXN | NRIX |
|---|---|---|
| Price | $57.31 | $14.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $30.58 |
| AVG Volume (30 Days) | 54.0K | ★ 933.5K |
| Earning Date | 04-29-2026 | 04-10-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $4.39 | $26.32 |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $54.97 | $8.18 |
| 52 Week High | $71.17 | $22.50 |
| Indicator | CNXN | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 39.62 | 42.06 |
| Support Level | $56.09 | $11.34 |
| Resistance Level | $59.71 | $16.47 |
| Average True Range (ATR) | 1.64 | 0.84 |
| MACD | -0.13 | 0.03 |
| Stochastic Oscillator | 25.55 | 31.51 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.